Serina Therapeutics, Inc.
SER
$2.57
$0.072.80%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 154.90% | 132.14% | -96.33% | -95.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | 154.90% | 132.14% | -96.33% | -95.90% |
| Cost of Revenue | 29.26% | 43.73% | 75.87% | 101.25% | 158.50% |
| Gross Profit | -30.82% | -43.12% | -75.44% | -318.95% | -935.93% |
| SG&A Expenses | 15.33% | 13.58% | 34.97% | 45.50% | 110.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.57% | 28.26% | 54.54% | 71.69% | 133.11% |
| Operating Income | -23.33% | -27.92% | -54.26% | -126.61% | -258.14% |
| Income Before Tax | -67.23% | -1,997.24% | -71.29% | -151.63% | -79.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.43% | -1,999.70% | -71.46% | -151.63% | -79.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -83.87% | -68.00% | -50.00% | -16.67% | 129.63% |
| Net Income | -68.18% | -2,164.86% | -72.17% | -152.87% | -79.67% |
| EBIT | -23.33% | -27.92% | -54.26% | -126.61% | -258.14% |
| EBITDA | -23.83% | -28.79% | -55.74% | -128.93% | -264.56% |
| EPS Basic | -46.44% | -8,452.99% | 60.93% | 54.42% | 63.48% |
| Normalized Basic EPS | -41.91% | -1,379.04% | 15.24% | -26.43% | 41.80% |
| EPS Diluted | -43.26% | -1,199.48% | 61.92% | 58.50% | 70.57% |
| Normalized Diluted EPS | -38.37% | -11,688.89% | 19.83% | 12.30% | 48.21% |
| Average Basic Shares Outstanding | 31.04% | 18.82% | 39.27% | 73.76% | 137.17% |
| Average Diluted Shares Outstanding | 24.76% | 8.24% | 24.23% | 28.74% | 45.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |